Get started
MannKind CorporationMannKind CorporationMannKind Corporation

MannKind Corporation

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

MNKD trade ideas

MNKD - risky catalyst playMannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. This is not a financial advice! Upcoming catalysts 03/08/2024 and 12/31/2024 Lots of block buys recently - as it seems someone knows something We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work. Keep an eye on 4.8 / 5.6 / 6.3 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains. SL under 4.3 (very tight) TPs approx. 7.0 (if data on 03/08 will be good) Most info on the chart. Trade carefully!
NASDAQ:MNKDLong
by meitshels_smell_trades
3
Watchlist 2023-02-22 #OSTK #MNKD #HD #TGNA #PANWSPY - did not make a higher high the entire day as sellers were firmly in control. Opening in the PM at the key 400 level. With the VIX finally spiking yesterday and bond prices making new lows., it appears like the price action and market internals indicate this short term bear action will continue. We would need to hear dovish comments from Bullard's speak at 2:00 PM ET today, but he has been the most hawkish member of the FED. The market will likely be low vol until that time today. Inside bar is highly likely. Being careful with any long attempts, need to see intense relative strength in the name or the spy setting up a buy setup. Short Watches: OSTK - reported a wider loss than anticipated, Revenue fell 34% year-over-year. RVOL only 1.4 so we'd need to see vol show up early. Below a falling 200EMA, below key 20.50 pivot with room to 18.00. Would prefer to see a test and rejection of 20.00 or 20.50 before getting involved as it's moved 1 ATR in the PM on relatively average RVOL. MNKD - reporting feb 23rd after the bell. It looks like people are positioning to lock in gains and get out of the name before earnings. Fake out over the ATH 5.60 and then a complete reversal, gapping down close to the key 5.00 pivot. Under this area we could see more seller, but we NEED to see that in the tape as we could be going counter trend with a rising 200 EMA and the 9 EMA is trending above the 21 EMA. What invalidates all those trends is the fakeout over 5.66. HD - continuation from yesterday's strong selling. No buys came in so any pops are opportunities to fade. . Long Watches: TGNA - justice department may be close to closing acquisition of TGNA. Cash deal for $ 24 per share - this is the highest possible price target, resistance at 22. RVOL nicely at 2.5 but ATR is only 0.40 cents. Wait and see. For an opening range break. PANW - beat-and-raise quarter amid macro slowdown. Over the key 178.80 range and pivot. Super bullish news. RVOL 2.5, moved 3 ATRs in the PM so we need to get in closer to the key pivot level if it holds. Target 192. I focus on names trading elevate RVOL>2, trading past key ranges and pivots, preferably with news catalysts.
NASDAQ:MNKD
by UnclePennybagss
Can MNKD be heading for a run up to $8.40'sMNKD has been consolidating for want seems to be forever, but since April of 2020 it's been catching a little bit of a pump which peaked sometime in March of this year. Since then it has created a symmetrical triangle. On its own a symmetrical triangle does not mean much, but if we look at other indicators like the weekly 200 MA, together with the RSI and the price action, we can try to put something together. What is showing us it that the price has been able to close above the 200 weekly MA for over 15 weeks in a roll. At the same time the 50 EMA on the weekly chart seems to be getting close to going over the 200 EMA and forming a GOLDEN CROSS. This still has not been confirmed, but as long as MNKD price can stay over $3.86, there is a good chance a run up to $8.90's is very possible.
NASDAQ:MNKDLong
by TheKingOfAces
MNKD Fibbin AgainMNKD is back at a frequent level of "traffic" this week. After doing a quick retracement we can see that the 618 area continues to act as a magnate a key pivot area. After bouncing off this last time, MNKD has continued higher on a decent multi-day move. Now, moving forward, a fundamental focus could be on what happens with its next potential commercial product, Tyvaso: MannKind’s collaboration partner, United Therapeutics (NASDAQ: UTHR), previously submitted an NDA to the FDA for its Tyvaso DPI product. This is a potential treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. In response to the strong Q2 performance, Michael Castagna, Chief Executive Officer of MannKind, said, “I am really proud of how our team has executed so far in 2021 supporting the growth of Afrezza and preparing for the potential commercial launch of Tyvaso DPI.” With this as the backdrop for a recent rally in MNKD stock, it could be a sign to have it as one of the penny stocks to watch heading into the second half of the month. Quote Source & Read More: Best Penny Stocks To Buy Right Now? 5 To Watch Before September
NASDAQ:MNKD
by PennyStocks101
Mannkind Corp ready for the pop MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI(TM) With New Drug Application Acceptance From The FDA. Mannkind's insulin inhaler Alfrezza since approval 7 years ago has not been a game changer for the company's revenue and bottom line although has marginally increase on monthly and yearly basics, the recent news I believe is the catalyst for MNKD to move into the next chapter for it's long term survival and it's stock price appreciation. I see the stock double in value by the approval date for Tyvaso expected by end of October 2021 to around $10 and once approved it should shoot to around $18.
NASDAQ:MNKD
by fkshen
Back In The Channel AgainMNKD is back in that Fib channel between the .5 and .382 levels. This was a previous channel earlier in the year. Now that the financing deal is done, will it finally see a prolonged uptrend without much interruption? " However, with fresh capital in hand, the company aims at advancing its current pipeline. This includes a Phase 3 clinical trial of its Afrezza inhaled insulin product in pediatric subjects. MannKind also explained that it wants to further the development of product candidates in its pipeline. The company may also use a portion of the proceeds for acquisitions or strategic investments in complementary businesses or technologies. Even with the pullback, analysts seem to remain bullish on the company. SVB Leerink most recently adjusted its price target on the stock. It had previously issued a $3 target but upped it to $5. The firm also carries an Outperform rating on the stock. " Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MNKD
by PennyStocks101
MNKD 10x Potential, High R/RRapidly Hiring. They have a proprietary drug delivery platform known as the Technosphere. They deliver drugs through the lungs instead of injection or pills. Afrezza their FDA approved drug is finally starting to generate sales after being fda approved years ago. They are also working on several other products for 2020. Huge accumulation range and due to very aggressive short sellers flooding the market with over 40 million additional shares over the years. All of these short sales will eventually be pressured to rebuy rapidly driving up price. There are also warrants that were delayed and expire in July. With the healthcare sector and biotech improving at a rapid pace, an effective product, all the catalysts are there.
NASDAQ:MNKDLong
by TradeRepository
2